All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Monday 3rd April, a poster session titled “Growth Factor and Hormone Receptors as Therapeutic Targets” took place.
During this session, a poster (2094 /21) titled “Dual inhibition of FLT3 and Src pathways by ON150030, a type 1 inhibitor, as a novel strategy for relapsed and refractory AML therapy” by Helya Ghaffari and colleagues from the Icahn School of Medicine at Mount Sinai, New York City, was on display.
Quizartinib inhibits FLT3-ITD in Acute Myeloid Leukemia (AML). Quizartinib binds to the inactive form of FLT3 but fails to inhibit FLT3-ITD harboring D835 mutation. In this study, the authors investigated the efficacy of ON150030, a type 1 inhibitor, which binds to the active form of FLT3.
In summary, ON15003 is a novel inhibitor with strong activity against SRC and FLT3 kinases. The authors highlighted that the distinct mode of action of ON15003 could be promising for therapy in AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox